Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4483-4487

  Panani, Anna D ^a   Maliaga, Katerina ^a   Babanaraki, Athanasia ^a   Bellenis, Ion ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Chromosome 9 numerical abnormalities; FISH technique; Genetic changes; Lung cancer; Non small cell lung cancer; p16CDKN2A gene deletion

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADENOCARCINOMA; ARTICLE; CANCER SURGERY; CHROMOSOME 9; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; GENE DELETION; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS;

EID: 75149146545     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Panani AD and Roussos C: Cytogenetic and molecular aspects of lung cancer. Cancer Lett 239: 1-9, 2006.
2. Huber RM. And Stratakis DF: Molecular oncology-perspectives in lung cancer. Lung Cancer 45: S209-S213, 2004.
3. Cheng S, Gao Y, Dong X, Lu Y, An Q, Tong T and Wang Y: Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung. Cancer Lett 162: S5-S10, 2001.
4. Wistuba I, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18: 643-650, 1999.
5. Mao L: Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 34: 527-534, 2001.
6. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen A-M, Salo J, Mattson K. Hollmen J, Knuutila S and Wikman H: Differentially expressed genes in non-small cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98-106, 2004.
7. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and Sculier JP: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719, 2001.
8. Huncharek M, Kuplnick B, Geschwind JF and Caubet JF: Prognostic significance of P53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 153: 219-226, 2000.
9. Yakut T, Egeli U and Gebitekin C: Investigation of C-MYC and P53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: By the FISH technique. Lung 181: 245-258, 2003.
10. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
11. INK4A and alterations of the 9p21-23 chromosome region in non-small cell lung cancer carcinomas: relationship with tumor growth parameters and ploidy status. Int J Cancer 89: 133-141, 2000.
12. INK4a and P53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5: 791-800, 1999.
13. Liggett WH and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
14. Stamouli M, Ferti AD, Panani AD, Raftakis J, Consoli C, Raptis SA and Young BD: Application of multiplex fluorescence in situ hybridization in the cytogenetic analysis of primary gastric carcinoma. Cancer Genet Cytogenet 135: 23-27, 2002.
15. Hopman AHN, Ramaekers FCS, Raap AK, Beck JLM, Deville P, Ploeg M and Vooijs GP: In situ hybridization as a tool to study numerical aberrations in solid bladder tumors. Histochemistry 89: 307-316, 1988.
16. Tanaka R, Wang D, Morishita Y, Inadome Y, Minami Y, Iijima T, Fucai S, Goya T and Noguchi M: Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103: 608-615, 2005.
17. Dessy E, Rossi E, Berenzi A, Tironi A, Benetti A and Grigolato P: Chromosome 9 instability and alterations of p16 gene in squamous cell carcinoma of the lung and in adjacent normal bronchi: FISH and immunohistochemical study. Histopathology 52: 475-482, 2008.
18. INK4a and tobacco carcinogen exposure in non-small cell lung cancer. Int J Cancer 118: 1364-1369, 2006.
19. INK4A and fragile histidine triad in non-small cell lung canrcinoma. Cancer 106: 2190-2199, 2006.
20. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K and Kato H: Cyclin D1, P16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34: 207-218, 2001.
21. Balsara BR and Testa JR: Chromosomal imbalances in human lung cancer. Oncogene 21: 6877-6883, 2002.
22. Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, Feder M, Jen J and Testa JR: Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosome Cancer 31: 282-287, 2001.
23. Hoglund M, Gisselsson D, Hansen GB and Mitelman F: Statistical dissection of cytogenetic patterns in lung cancer reveals multiple modes of karyotypic evolution independent of histological classification. Cancer Genet Cytogenet 154: 99-109, 2004.
24. INK4A) gene in chronic lymphocytic leukemia. Eur J Haematol 76: 230-236, 2006.